Search clinical trials for: Poly(ADP-ribose) Polymerase Inhibitors

Total 2226 results

Armando Santoro, MD
GlaxoSmithKline; Istituto Clinico Humanitas

Not yet recruiting

Niraparib and Temozolomide in Patients Glioblastoma (ONC-2022-001)

Glioma, Malignant

Italy
Institute of Cancer Research, United Kingdom
Royal Marsden NHS Foundation Trust

Not yet recruiting

SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy (SOPRANO)

Ovarian Cancer Recurrent

United Kingdom
Grupo Español de Tratamiento de Tumores de Cabeza...
GlaxoSmithKline; MFAR

Recruiting

Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma (RADIAN)

Head and Neck Squamous Cell Carcinoma

Spain
Seoul National University Hospital

Recruiting

Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency

Advanced Breast Cancer

Korea, Republic of
zr Pharma & GmbH
Foundation Medicine; Myriad Genetics, Inc.

Completed

A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) (ARIEL2)

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

United States, Spain, Canada, Australia, United Kingdom, France
zr Pharma & GmbH

Completed

Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib (AME)

Solid Tumor

Hungary
University College, London
AstraZeneca

Withdrawn

Phase I Study of Olaparib With Cisplatin Based Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck (ORCA)

Carcinoma, Squamous Cell
Sun Yat-sen University

Not yet recruiting

Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer

NSCLC | Non-small Cell Lung Cancer

China
Memorial Sloan Kettering Cancer Center

Active, not recruiting

A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer

Prostate Cancer | Castration-resistant Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Prostate Neoplasm

United States
University Hospital Southampton NHS Foundation...
British Lung Foundation; University of Southampton

Active, not recruiting

Niraparib Efficacy in Patient With Unresectable Mesothelioma (NERO)

Mesothelioma, Malignant

United Kingdom
Pfizer

Terminated

Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

Locally Advanced or Metastatic Solid Tumors | Genes, BRCA 1

United States, Belgium, Spain, Denmark, Japan, France, Italy, Netherlands, United Kingdom
Yale University

Completed

TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer

Colorectal Cancer

United States
Pfizer

Completed

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | NSCLC | Prostate Cancer | Advanced Solid Tumors | Solid Tumors

United States, Australia
Merck Sharp & Dohme LLC

Completed

Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)

Melanoma | Glioblastoma Multiforme | Recurrence of Solid Tumor
John Diaz
Merck Sharp & Dohme LLC; Florida Department of Health

Active, not recruiting

Pembrolizumab and Olaparib in Cervical Cancer Patients

Cervical Cancer | Cervical Carcinoma

United States
GlaxoSmithKline

Active, not recruiting

Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer (ZEAL-1L)

Lung Cancer, Non-Small Cell

Argentina, France, Spain, Italy, Belgium, Korea, Republic of, United States, Mexico, Hungary, Sweden, Turkey, Ireland, Greece, Russian Federation, Germany, Netherlands, Bulgaria, Romania, Brazil, United Kingdom, Poland, Australia, C... and more
University of Washington
AstraZeneca

Terminated

Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma

Castration-Resistant Prostate Carcinoma | Prostate Adenocarcinoma

United States
University of Alabama at Birmingham

Terminated

CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients (BRCA)

Ovarian Cancer | Resistant BRCA Wild-Type Ovarian Cancer

United States
The First Affiliated Hospital of Soochow University

Recruiting

Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS

Hematopoietic Stem Cell Transplantation | CMV Infection

China
Samsung Medical Center

Not yet recruiting

PALbociclib Endocrine Therapy Followed by Talazo vs. Talazoz-Atezo Study (Young-PALETTA)

Premenopausal HR+/HER2- Metastatic Breast Cancer

Korea, Republic of
ARCAGY/ GINECO GROUP
Tesaro, Inc.

Active, not recruiting

Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib (ROCSAN)

Ovarian Carcinosarcoma | Endometrial Carcinosarcoma

France
Ellipses Pharma

Withdrawn

EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer

Gastric Cancer | Small-cell Lung Cancer

China, Korea, Republic of, Taiwan
University of Maryland, Baltimore
Pfizer; Van Andel Research Institute

Completed

Decitabine and Talazoparib in Untreated AML and R/R AML (1565GCC)

Acute Myeloid Leukemia

United States
Hellenic Cooperative Oncology Group
AstraZeneca

Completed

Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck. (OPHELIA)

Squamous Cell Carcinoma of the Head and Neck

Greece
The Christie NHS Foundation Trust
AstraZeneca; Cancer Research UK

Unknown

Radiotherapy & Olaparib in COmbination for Carcinoma of the Oesophagus (ROCOCO)

Carcinoma of the Oesophagus

United Kingdom
Pamela Munster
Clovis Oncology, Inc.

Completed

Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair

Solid Tumor, Unspecified, Adult

United States
Istituto Scientifico Romagnolo per lo Studio e...
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC) (THOR)

SCLC,Extensive Stage

Italy
Case Comprehensive Cancer Center

Completed

Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes

Metastatic or Unresectable Melanoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Progressive Disease | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Platinum-Resistant Ovarian Carcinoma | High Grade Ovarian... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier | Ovarian Epithelial Tumor

United States
University of California, San Francisco
GlaxoSmithKline

Recruiting

Combination Therapy in Cancers With Mutations in DNA Repair Genes

Metastatic Solid Tumor | BRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | ATM Gene Mutation

United States
Cao Weijie

Recruiting

Observational Clinical Study of Letermovir for Preventing CMV Infection After Allo-HSCT

Letemovir for the Prevention of CMV Infection After Allo-HSCT

China
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT

The Incidence of Peripheral Blood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After Transplantation
Artios Pharma Ltd

Recruiting

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients

Advanced Solid Tumor | Metastatic Solid Tumor

United States
AGO Research GmbH

Recruiting

WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC (WoO)

Epithelial Ovarian Cancer

Germany
OHSU Knight Cancer Institute
Eli Lilly and Company; GlaxoSmithKline; Oregon Health and Science University

Active, not recruiting

Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Prognostic... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Metastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Refractory Malignant Neoplasm | PALB2 Gene Mutation | ATM Gene Mutation

United States
AstraZeneca

Completed

To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours

Solid Tumours

Denmark, Belgium, United Kingdom, Netherlands
University of Turin, Italy
Tesaro, Inc.

Completed

Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemotherapy

Urothelial Carcinoma

Italy
National Cancer Institute (NCI)

Completed

A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors

Astrocytoma | Ependymoma | Medulloblastoma | Pontine Glioma | PNET

United States
National Cancer Institute (NCI)

Recruiting

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

Breast Neoplasms | Colorectal Neoplasms

United States
Zhonglin Hao
Clovis Oncology, Inc.

Active, not recruiting

Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma

Small Cell Lung Cancer

United States
Hoffmann-La Roche

Completed

A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

Breast Cancer | Ovarian Cancer | Prostate Cancer

United States, Korea, Republic of, Italy, Australia, Spain
National Cancer Institute (NCI)

Withdrawn

Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Ovarian Serous Adenocarcinoma | Primary Peritoneal... and other conditions
Massachusetts General Hospital
University of Pennsylvania; Duke University; Sibley Memorial Hospital

Recruiting

Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer (NADiR)

Breast Cancer | Triple Negative Breast Cancer

United States
Marc Dall'Era, MD
National Cancer Institute (NCI); Janssen, LP

Recruiting

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Prostate Carcinoma | RAD51C Gene Mutation | BRIP1 Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | CDK12 Gene Mutation | CHEK1 Gene Mutation | DNA Damage Response Gene Mutation | DNA Repair Gene Mutation | FANCA Gene Mutation and other conditions

United States
Pfizer
Astellas Pharma Inc

Active, not recruiting

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Prostate Cancer

United States, Finland, China, France, Spain, Hungary, United Kingdom, Korea, Republic of, Canada, Czechia, Taiwan, Belgium, Australia, Argentina, Japan, Germany, India, Turkey, Slovakia, Russian Federation, Bulgaria, Italy, Ukraine, ... and more
Vastra Gotaland Region
Advanced Accelerator Applications

Active, not recruiting

177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours (LuPARP)

Thymoma | Neuroendocrine Tumors | Mesothelioma | Clinical Trial, Phase I

Sweden
Ellipses Pharma

Completed

EP0057 in Combination With Olaparib in Advanced Ovarian Cancer

Ovarian Cancer

United States, United Kingdom, Hungary
Sandoz

Completed

A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With BRCA Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer

Breast Cancer | Ovarian Cancer

India

Search clinical trials for: Poly(ADP-ribose) Polymerase Inhibitors

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations